Allogene Therapeutics (ALLO) has disclosed a new risk, in the Innovation / R&D category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Allogene Therapeutics faces uncertainty over whether fludarabine and cyclophosphamide (FC) alone can achieve adequate lymphodepletion to support cema-cel’s efficacy in the ALPHA3 trial, after discontinuation of ALLO-647 due to a Grade 5 SAE. If FC proves insufficient and the study design must be amended to enhance lymphodepletion, the resulting trial delays could impair regulatory timelines and materially weaken the company’s business and financial outlook.
The average ALLO stock price target is $8.71, implying 262.92% upside potential.
To learn more about Allogene Therapeutics’ risk factors, click here.